


JC07 Rec'd PCT/PTO 12 APR 2005

Date: April 11, 2005 I hereby certify that, on the date indicated above, I deposited this paper with identified attachments and/or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "First Class Mail to Addressee" service.



Donald S. Prater
Name (Print)

Donald S. Prater
Signature

#2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	DOI et al.)	Examiner:	Unassigned
)		
Application No.:	10/519,465)	Group Art Unit:	Unassigned
)		
Filed:	December 27, 2004)	Confirmation No.:	Unassigned
)		
Docket No.:	3190-069)	Customer No.:	33432

For: MKK7 ACTIVATION INHIBITOR

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

April 11, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided.

This Information Disclosure Statement is being submitted after expiration of the three-month period following filing of the above-captioned application, but before an Office Action on the merits and before any Final Office Action or Notice of Allowance.

Should a first Office Action cross in the mail with the filing of this Information Disclosure statement, then applicants respectfully petition under 37 C.F.R. § 1.97(c) to consider the documents set forth in the Information Disclosure Statement.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and


1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925 and please consider this a petition.

Respectfully submitted,


Luke A. Kilyk
Reg. No. 33,251

Atty. Docket No.: 3190-069
KILYK & BOWERSOX, P.L.L.C.
53 A East Lee Street
Warrenton, VA 20186
Tel.: (540) 428-1701
Fax: (540) 428-1720
Enclosures: PTO-1449, w/ 26 Documents

FORM PTO-1449 (REV 1/00)	Atty. Docket No. 3190-069	Application No. 10/519,465
INFORMATION DISCLOSURE STATEMENT	Applicant: Doi et al.	
	Filing Date: December 27, 2004	Group Art Unit: Unassigned



	Frost, et al., "Actions of Rho family small G proteins and P21-activated protein kinases on mitogen-activated protein kinase family members," <i>Mol. Cell. Biol.</i> , 1996, Vol. 16, No. 7, pp. 3707-3713
	Abo et al., "PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filopodia," <i>EMBO J.</i> , 1998, Vol. 17, No. 22, pp. 6527-6540.
	Bazenet et al., "The small GTP-binding protein Cdc42 is required for nerve growth factor withdrawal-induced neuronal death," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 1998, Vol. 95, pp. 3984-3989.
	Urano et al., "IRE1 and efferent signaling from the endoplasmic reticulum," <i>J. Cell Sci.</i> , 2000, Vol. 113, pp. 3697-3702
	Urano et al., "Coupling of stress in the ER to Activation of JNK protein kinases by transmembrane protein kinase IRE1," <i>Science</i> , 2000, Vol. 287, pp. 664-666.
	Yoneda et al., "Activation of caspase-12, an endoplasmic reticulum (ER) resident caspase, through tumor necrosis factor receptor-associated factor 2-dependent mechanism in response to the ER stress," <i>J. Biol. Chem.</i> , 2001, Vol. 276, No. 17, pp. 13935-13940.
	Tassi et al., "Human JIK, a novel member of the STE20 kinase family that inhibits JNK and is negatively regulated by epidermal growth factor," <i>J. Biol. Chem.</i> , 1999, Vol. 274, No. 47, pp. 33287-33295.
	Zhang et al., "Cloning of DPK, a novel dendritic cell-derived protein kinase activating the ERK1/ERK2 and JNK/SAPK pathways," <i>Biochem. Biophys. Res. Commun.</i> , 2000, Vol. 274, pp. 872-879.
	Zhang et al., "Activation of JNK and transcriptional repressor ATF3/LRF1 through the IRE1/TRAF2 pathway is implicated in human vascular endothelial cell death by homocysteine," <i>Biochem. Biophys. Res. Commun.</i> , 2001, Vol. 289, pp. 718-724.
	<i>Cell Technologies</i> , 2001, Vol. 20, No. 11. (with partial English translation)
	Copy of International Preliminary Examination Report for PCT/JP2003/008179 (English translation)
EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

FORM PTO-1449 (REV. 10/00)	Atty. Docket No. 3190-069	Application No. 10/519,465
INFORMATION DISCLOSURE STATEMENT	Applicant: Doi et al.	
	Filing Date: December 27, 2004	Group Art Unit: Unassigned

U.S. PATENT DOCUMENTS						
EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE, IF APPROPRIATE
	6,465,618 B1	10/15/02	Nishida et al.	530	350	
	2004/0121398 A1	06/24/04	Doi et al.	435	7.1	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Xie et al., "Crystal structure of JNK3: a kinase implicated in neuronal apoptosis," <i>Structure</i> , 1998, Vol. 6, No. 8, pp. 983-991
	Ikeda et al., "Mixed lineage kinase LZK forms a functional signaling complex with JIP-1, a scaffold protein of the c-Jun NH ₂ -Terminal kinase pathway," <i>Journal of Biochemistry</i> , 2001 No. 130, pp. 773-781
	Yamauchi et al., "Differential regulation of mitogen-activated protein kinase kinase 4 (MKK4) and 7 (MKK7) by signaling from G protein β γ sub-unit in human embryonal kidney 293 cells," <i>The Journal of Biological Chemistry</i> , 1999, No. 274, Vol. 4, pp. 1957-1965
	Yao et al., Activation of stress-activated protein kinases/c-Jun n-terminal protein kinases (SAPKs/JNKs) by a novel mitogen-activated protein kinase kinase (MKK7)," <i>The Journal of Biological Chemistry</i> , 1997, Vol. 272, No. 51, pp. 32378-32383.
	Tournier et al., "The MKK7 gene encodes a group of c-Jun NH ₂ -Terminal kinase kinases," <i>Molecular and Cellular Biology</i> , 1999, Vol. 19, No. 2, pp. 1569-1581
	Chen et al., "Mammalian c-Jun N-terminal kinase pathway and STE20-related kinases," <i>Gene Therapy and Molecular Biology</i> , 1999, Vol. 4, pp. 83-98
	Dan et al., "The Ste20 group kinases as regulators of MAP kinase cascades," <i>Trends in Cell Biology</i> , 2001, Vol. 11, No. 5, pp. 220-230
	Eilers et al., "Role of the Jun kinase pathway in the regulation of c-Jun Expression and Apoptosis in Sympathetic Neurons," <i>J. Neurosci.</i> , 1998, Vol. 18, No. 5, pp. 1713-1724
	Ham et al., "A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death," <i>Neuron</i> , 1995, Vol. 14, pp. 927-939
	Yang et al., "Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene," <i>Nature</i> , 1997, Vol. 389, pp. 865-870.
	Moriguchi et al., "A novel SAPK/JNK kinase, MKK7, stimulated by TNF α and cellular stresses," <i>EMBO J.</i> , 1997, Vol. 16, No. 23, pp. 7045-7053.
	Foltz et al., "Human mitogen-activated protein kinase kinase 7 (MKK7) is a highly conserved c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) activated by environmental stresses and physiological stimuli," <i>J. Biol. Chem.</i> , 1998, Vol. 273, No. 15, pp. 9344-9351.
	Yang et al., "Targeted disruption of the MKK4 gene causes embryonic death, inhibition of c-Jun NH ₂ -terminal kinase activation, and defects in AP-1 transcriptional activity," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 1997, Vol. 94, No. 7, pp. 3004-3009.
	Bagrodia et al., "Cdc42 and PAK-mediated signaling leads to jun kinase and p38 mitogen-activated protein kinase activation," <i>J. Biol. Chem.</i> , 1995, Vol. 270, No. 47, pp. 27995-27998.
	Brown et al., "Human Ste20 homologue hPAK1 links GTPases to the JNK MAP kinase pathway," <i>Curr. Biol.</i> , 1996, Vol. 6, No. 5, pp. 598-605.